FT Rethink
How to cure an ailing antibiotics business?
Developing new antibiotics can be a long and costly process with no guarantee of profit. While many pharma companies have dropped out of the business, the FT’s Aanu Adeoye explores how others are finding ways to bring new, desperately needed drugs to market.
As the world changes at lightning speed, the FT Rethink series explores how to navigate transformative shifts shaping the future, from geopolitics and climate to industry, energy and health. The channel alternates between independent reporting from FT journalists and business perspectives from Lombard Odier.
About FT Channels
FT Channels, a partnership destination that combines impactful and enriching multimedia content to spark curiosity and encourage discovery. Each vertical brings expert insights from the Financial Times and our Partners into the most pressing issues of our time.
FT Rethink
FT Channels, a partnership destination that combines impactful and enriching multimedia content to spark curiosity and encourage discovery. Each vertical brings expert insights from the Financial Times and our Partners into the most pressing issues of our time.
As the world changes at lightning speed, the FT Rethink series explores how to navigate transformative shifts shaping the future, from geopolitics and climate to industry, energy and health. The channel alternates between independent reporting from FT journalists and business perspectives from Lombard Odier.